Alkermes PLC ALKS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALKS is a good fit for your portfolio.
News
-
Pharmaceuticals in the Environment
-
Alkermes to Participate in Two Upcoming Investor Conferences
-
Environmental Protection & Sustainability at Alkermes
-
Alkermes Celebrates #Movember for Men’s Health Awareness Month
-
Alkermes' Waste Optimization Highlights
-
Alkermes Completes Separation of Oncology Business
-
Our Commitment to Caregivers
-
Product Stewardship and Environmental Impact at Alkermes
Trading Information
- Previous Close Price
- $23.55
- Day Range
- $23.60–24.24
- 52-Week Range
- $22.01–33.71
- Bid/Ask
- $23.77 / $23.78
- Market Cap
- $3.97 Bil
- Volume/Avg
- 2.3 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 17.57
- Price/Sales
- 2.50
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,280
- Website
- https://www.alkermes.com
Competitors
Valuation
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Price/Earnings (Normalized) | 17.57 | 14.45 |
Price/Book Value | 2.90 | 5.13 |
Price/Sales | 2.50 | 4.53 |
Price/Cash Flow | 10.78 | 17.82 |
Price/Earnings
ALKS
JNJ
Financial Strength
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Quick Ratio | 2.44 | 0.86 |
Current Ratio | 2.91 | 1.21 |
Interest Coverage | 9.85 | 20.16 |
Quick Ratio
ALKS
JNJ
Profitability
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Return on Assets (Normalized) | 11.19% | 14.22% |
Return on Equity (Normalized) | 20.12% | 35.35% |
Return on Invested Capital (Normalized) | 14.75% | 22.60% |
Return on Assets
ALKS
JNJ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Njkfc | $81.2 Bil | |
MKKGY
| Merck KGaA ADR | Mybdgmj | $75.2 Bil | |
HLN
| Haleon PLC ADR | Jynh | $39.1 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Sps | $11.3 Bil | |
VTRS
| Viatris Inc | Phrs | $11.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Pgqy | $10.8 Bil | |
CTLT
| Catalent Inc | Slbtdlz | $7.1 Bil | |
PRGO
| Perrigo Co PLC | Jff | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Kppqzf | $2.8 Bil | |
CURLF
| Curaleaf Holdings Inc | Zcx | $2.8 Bil |